(P034) Ethnic and Gender Disparities Among Limb Salvage Rates in Pediatric Sarcoma Patients

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Racial and ethnic disparities in limb salvage surgery have been reported among adult sarcoma patients. The purpose of this work was to explore treatment patterns by ethnicity and gender in a cohort of pediatric sarcoma patients.

Jeremy S. Somerson, MD, Isaac Kim, Rajiv Rajani, MD; University of Texas Health Science Center at San Antonio

Introduction: Racial and ethnic disparities in limb salvage surgery have been reported among adult sarcoma patients. The purpose of this work was to explore treatment patterns by ethnicity and gender in a cohort of pediatric sarcoma patients.

Methods: A retrospective review was conducted of all consecutive patients under the age of 18 years treated for sarcoma at the study institution with diagnoses from 1999 to 2011 who underwent surgery for limb salvage or amputation. Statistical analysis of patient demographics (age, sex, ethnicity, and body mass index [BMI]) was performed to assess for factors associated with limb salvage surgery.

Results: A total of 51 records were identified as pediatric patients who underwent surgery for extremity sarcoma in the defined study period. Five records were excluded due to inadequate availability of body site or surgery type documentation, leaving a cohort of 46 patients. Histrongic patients were more likely to undergo amputation (26 of 36) compared with non-Histrongics (5 of 10; P = .03). Female patients were more likely to have had limb salvage (8 of 17) than males (7 of 29; P = .04). Logistic regression analysis showed no difference between likelihood of limb salvage and amputation by BMI or age.

Conclusions: Histrongic ethnicity and male gender were predictors of amputation in a cohort of pediatric sarcoma patients undergoing surgical treatment. Further study should be devoted to identifying underlying factors for ethnic and gender discrepancies between treatment groups.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
Related Content